# EDGAR Filing Document

**Accession Number:** 0001100663
**File Stem:** 0001410368-25-043397
**Filing Date:** 2025-12
**Character Count:** 33276
**Document Hash:** ba30729f9d530684c6aad26ba52cc08a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-25-043397.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001410368-25-043397

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251031

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iSHARES TRUST
- **CENTRAL INDEX KEY:** 0001100663

**ORGANIZATION NAME:**
- **EIN:** 943351276
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-09729
- **FILM NUMBER:** 251606798

**BUSINESS ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105
- **BUSINESS PHONE:** (415) 670-2000

**MAIL ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISHARES TRUST
- **DATE OF NAME CHANGE:** 19991213

## Series and Classes Contracts Data

### iShares Genomics Immunology and Healthcare ETF (Series ID: S000065599)

| Class ID   | Class Name                                     | Ticker Symbol   |
|:---|:---|:---|
| C000212225 | iShares Genomics Immunology and Healthcare ETF | IDNA            |

## Nport-Ex

Schedule of Investments (unaudited)

October 31, 2025

**iShares® Genomics Immunology and Healthcare ETF** 

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Canada — 2.4%** | **Canada — 2.4%** | **Canada — 2.4%** |
| AbCellera Biologics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 557801 | $3095796 |
| **China — 4.2%** | **China — 4.2%** | **China — 4.2%** |
| BeOne Medicines Ltd., Class H<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 221700 | 5330178 |
| **Denmark — 4.5%** | **Denmark — 4.5%** | **Denmark — 4.5%** |
| Genmab A/S<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 19980 | 5698851 |
| **France — 4.8%** | **France — 4.8%** | **France — 4.8%** |
| Sanofi SA | &nbsp;&nbsp;&nbsp; 43793 | 4430222 |
| Valneva SE<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 354772 | 1655364 |
|  |  | 6085586 |
| **Germany — 3.3%** | **Germany — 3.3%** | **Germany — 3.3%** |
| BioNTech SE, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 40643 | 4223214 |
| **Japan — 3.5%** | **Japan — 3.5%** | **Japan — 3.5%** |
| Ono Pharmaceutical Co. Ltd. | &nbsp;&nbsp;&nbsp; 34000 | 414916 |
| Takeda Pharmaceutical Co. Ltd. | &nbsp;&nbsp;&nbsp; 148500 | 4007643 |
|  |  | 4422559 |
| **South Korea — 1.8%** | **South Korea — 1.8%** | **South Korea — 1.8%** |
| SK Bioscience Co. Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 64356 | 2285217 |
| **Switzerland — 3.5%** | **Switzerland — 3.5%** | **Switzerland — 3.5%** |
| Roche Holding AG, NVS | &nbsp;&nbsp;&nbsp; 13537 | 4384907 |
| **United Kingdom — 8.4%** | **United Kingdom — 8.4%** | **United Kingdom — 8.4%** |
| AstraZeneca PLC | &nbsp;&nbsp;&nbsp; 30234 | 4987054 |
| GSK PLC | &nbsp;&nbsp;&nbsp; 215446 | 5044332 |
| Mereo Biopharma Group PLC, ADR<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 358296 | 680762 |
|  |  | 10712148 |
| **United States — 63.3%** | **United States — 63.3%** | **United States — 63.3%** |
| Arcellx Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 64747 | 5843417 |
| Arcturus Therapeutics Holdings Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 61849 | 616635 |
| Arcus Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 159122 | 3137886 |
| Beam Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 8726 | 218237 |
| BioCryst Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 399387 | 2923513 |
| Celcuity Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 76832 | 5928357 |
| CRISPR Therapeutics AG<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 8023 | 513392 |
| Exelixis Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 102470 | 3962515 |
| Geron Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1502885 | 1893635 |
| Ginkgo Bioworks Holdings Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 93180 | 1210408 |
| ImmunityBio Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 228691 | 548858 |
| Immunome Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 191296 | 3074127 |
| Incyte Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 64116 | 5993564 |
| Intellia Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 9344 | 117921 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **United States (continued)** | **United States (continued)** | **United States (continued)** |
| Iovance Biotherapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 676418 | $1332543 |
| Janux Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 123491 | 3545427 |
| Kura Oncology Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 204939 | 2104724 |
| Ligand Pharmaceuticals Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1823 | 348758 |
| Merck & Co. Inc. | &nbsp;&nbsp;&nbsp; 55835 | 4800693 |
| Moderna Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 160570 | 4361081 |
| Novavax Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 367631 | 3088100 |
| OmniAb Inc., 12.50 Earnout Shares<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 19498 |  |
| OmniAb Inc., 15.00 Earnout Shares<sup>(c)</sup> | &nbsp;&nbsp;&nbsp; 19498 |  |
| ORIC Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 99412 | 1308262 |
| Pacific Biosciences of California Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 657930 | 1539556 |
| Regeneron Pharmaceuticals Inc. | &nbsp;&nbsp;&nbsp; 8941 | 5827744 |
| Revolution Medicines Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 107306 | 6313885 |
| Rigel Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 43277 | 1366688 |
| Twist Bioscience Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 139666 | 4593615 |
| Vir Biotechnology Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 221896 | 1322500 |
| Xencor Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 166400 | 2447744 |
|  |  | 80283785 |
| **Total Long-Term Investments — 99.7%** <br>**(Cost: $122,831,866)** | **Total Long-Term Investments — 99.7%** <br>**(Cost: $122,831,866)** | 126522241 |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 19.1%** | **Money Market Funds — 19.1%** | **Money Market Funds — 19.1%** |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency <br> Shares, 4.27%<sup>(d)(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp; 24118013 | 24130072 |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency Shares, <br> 4.05%<sup>(d)(e)</sup><br>| &nbsp;&nbsp;&nbsp; 150000 | 150000 |
| **Total Short-Term Securities — 19.1%** <br>**(Cost: $24,279,914)** | **Total Short-Term Securities — 19.1%** <br>**(Cost: $24,279,914)** | 24280072 |
| **Total Investments — 118.8%** <br>**(Cost: $147,111,780)** | **Total Investments — 118.8%** <br>**(Cost: $147,111,780)** | 150802313 |
| **Liabilities in Excess of Other Assets — (18.8)%** | **Liabilities in Excess of Other Assets — (18.8)%** | (23887055)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | $126915258 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of this security is on loan.

<sup>(c)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(d)</sup> Affiliate of the Fund.

<sup>(e)</sup> Annualized 7-day yield as of period end.

<sup>(f)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

------

Schedule of Investments (unaudited)(continued)

October 31, 2025

**iShares® Genomics Immunology and Healthcare ETF** 

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2025 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*07/31/25*<br>| &nbsp;&nbsp; *Proceeds* <br>*from Sales*<br>| *Net Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*10/31/25*<br>| *Shares* <br>*Held at* <br>*10/31/25*<br>| *Income* | &nbsp;&nbsp; *Capital* <br>*Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency <br> Shares<br>| $17020058<br> $7108212 <br><sup>(a)</sup><br>| $— | $1644 | $158 | $24130072 | 24118013 | $47055 <br><sup>(b)</sup><br>| $— |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency <br> Shares<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40000<br> 110000 <br><sup>(a)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 150000 | 150000 | &nbsp;&nbsp;&nbsp;&nbsp; 728 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |
|  |  |  | $1644 | $158 | $24280072 |  | $47783 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

**Derivative Financial Instruments Outstanding as of Period End**

**Futures Contracts** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Description* | &nbsp;&nbsp; *Number of* <br>*Contracts*<br>| &nbsp;&nbsp; *Expiration* <br>*Date*<br>| *Notional* <br>*Amount* <br>*(000)*<br>| &nbsp;&nbsp; *Value/* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>|
| Long Contracts |  |  |  |  |
| &nbsp;&nbsp;&nbsp; E-Mini Health Care Select Sector Index | 2 | 12/19/25 | &nbsp;&nbsp; $293 | $8833 |

---

**Fair Value Hierarchy as of Period End** 

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges that the Fund has the ability to access for identical assets or liabilities;

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks | &nbsp;&nbsp; $88283557 | &nbsp;&nbsp; $38238684 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $126522241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 24280072 | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 24280072 |
|  | &nbsp;&nbsp; $112563629 | &nbsp;&nbsp; $38238684 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $150802313 |

---

------

Schedule of Investments (unaudited)(continued)

October 31, 2025

**iShares® Genomics Immunology and Healthcare ETF** 

**Fair Value Hierarchy as of Period End (continued)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Derivative Financial Instruments<sup>(a)</sup>  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equity Contracts | &nbsp;&nbsp; $8833 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $— | &nbsp;&nbsp; $8833 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Derivative financial instruments are futures contracts. Futures contracts are valued at the unrealized appreciation (depreciation) on the instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation** | **Portfolio Abbreviation** |
| ADR | American Depositary Receipt |
| NVS | Non-Voting Shares |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** iShares Trust

- **b. Investment Company Act file number:** 811-09729

- **c. CIK number of Registrant:** 0001100663

- **d. LEI of Registrant:** 5493000860OXIC4B5K91

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 400 Howard Street

  - **City:** San Francisco

  - **State:** CA

  - **Foreign country:** US

  - **Zip / Postal Code:** 94105

  - **Telephone number:** 800-474-2737

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares Genomics Immunology and Healthcare ETF

- **b. EDGAR series identifier (if any):** S000065599

- **c. LEI of Series:** 549300KS9JS2Z81CYC21

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2025-10-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $173879988.33

**Total Liabilities:** $45696362.01

**Net Assets:** $128183626.32

**Cash Not Reported:** $56094.06

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000212225 | 4.48%                | 6.90%                | 7.27%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $549271.05               | $4114079.32                                |
| Month 2  | $1179.49                 | $7520514.20                                |
| Month 3  | $-882.06                 | $8661647.59                                |

### Schedule of Portfolio Investments

| Name                                           | Title                                                 | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| AbCellera Biologics Inc                        | AbCellera Biologics Inc                               | CUSIP: 00288U106<br>LEI: 9845000861BC95FF9F73 | Long             | EC               | CORP              | CA        |    563379 | NS      | $3126753.45   | 2.44%             |  |  |  | No            |                  1 | On Loan: —       |
| Arcellx Inc                                    | Arcellx Inc                                           | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     65394 | NS      | $5901808.50   | 4.60%             |  |  |  | No            |                  1 | On Loan: —       |
| Arcus Biosciences Inc                          | Arcus Biosciences Inc                                 | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    160713 | NS      | $3169260.36   | 2.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcturus Therapeutics Holdings Inc             | Arcturus Therapeutics Holdings Inc                    | CUSIP: 03969T109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     62467 | NS      | $622795.99    | 0.49%             |  |  |  | No            |                  1 | On Loan: —       |
| Beam Therapeutics Inc                          | Beam Therapeutics Inc                                 | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      8813 | NS      | $220413.13    | 0.17%             |  |  |  | No            |                  1 | On Loan: —       |
| BioCryst Pharmaceuticals Inc                   | BioCryst Pharmaceuticals Inc                          | CUSIP: 09058V103<br>LEI: 549300Z0INP1Z5NP6J59 | Long             | EC               | CORP              | US        |    403380 | NS      | $2952741.60   | 2.30%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                    | BioNTech SE                                           | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |     41049 | NS      | $4265401.59   | 3.33%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                                | AstraZeneca PLC                                       | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     30536 | NS      | $5036868.28   | 3.93%             |  |  |  | No            |                  2 | On Loan: No      |
| Celcuity Inc                                   | Celcuity Inc                                          | CUSIP: 15102K100<br>LEI: 25490070W7UU7W2SEY87 | Long             | EC               | CORP              | US        |     77600 | NS      | $5987616.00   | 4.67%             |  |  |  | No            |                  1 | On Loan: —       |
| Exelixis Inc                                   | Exelixis Inc                                          | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |    103494 | NS      | $4002112.98   | 3.12%             |  |  |  | No            |                  1 | On Loan: —       |
| Geron Corp                                     | Geron Corp                                            | CUSIP: 374163103<br>LEI: 549300T282D7Z2YESL90 | Long             | EC               | CORP              | US        |   1517913 | NS      | $1912570.38   | 1.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Ginkgo Bioworks Holdings Inc                   | Ginkgo Bioworks Holdings Inc                          | CUSIP: 37611X209<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     94111 | NS      | $1222501.89   | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| ImmunityBio Inc                                | ImmunityBio Inc                                       | CUSIP: 45256X103<br>LEI: 529900J9XLBR4HFL4B83 | Long             | EC               | CORP              | US        |    230977 | NS      | $554344.80    | 0.43%             |  |  |  | No            |                  1 | On Loan: —       |
| Immunome Inc                                   | Immunome Inc                                          | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    193208 | NS      | $3104852.56   | 2.42%             |  |  |  | No            |                  1 | On Loan: —       |
| Incyte Corp                                    | Incyte Corp                                           | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |     64757 | NS      | $6053484.36   | 4.72%             |  |  |  | No            |                  1 | On Loan: —       |
| Intellia Therapeutics Inc                      | Intellia Therapeutics Inc                             | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |      9437 | NS      | $119094.94    | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |
| Genmab A/S                                     | Genmab A/S                                            | CUSIP: 000000000<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |     20179 | NS      | $5755611.80   | 4.49%             |  |  |  | No            |                  2 | On Loan: No      |
| Iovance Biotherapeutics Inc                    | Iovance Biotherapeutics Inc                           | CUSIP: 462260100<br>LEI: 2549002L8WT2ACU5Q878 | Long             | EC               | CORP              | US        |    683182 | NS      | $1345868.54   | 1.05%             |  |  |  | No            |                  1 | On Loan: —       |
| Janux Therapeutics Inc                         | Janux Therapeutics Inc                                | CUSIP: 47103J105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    124725 | NS      | $3580854.75   | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Kura Oncology Inc                              | Kura Oncology Inc                                     | CUSIP: 50127T109<br>LEI: 5493005QORQTZCZYOP39 | Long             | EC               | CORP              | US        |    206988 | NS      | $2125766.76   | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Ligand Pharmaceuticals Inc                     | Ligand Pharmaceuticals Inc                            | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |      1841 | NS      | $352201.71    | 0.27%             |  |  |  | No            |                  1 | On Loan: —       |
| Sanofi SA                                      | Sanofi SA                                             | CUSIP: 000000000<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |     44230 | NS      | $4474429.74   | 3.49%             |  |  |  | No            |                  2 | On Loan: No      |
| Merck & Co Inc                                 | Merck & Co Inc                                        | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     56393 | NS      | $4848670.14   | 3.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Mereo Biopharma Group PLC                      | Mereo Biopharma Group PLC                             | CUSIP: 589492107<br>LEI: 213800U8JQHIJOS5AS09 | Long             | EC               | CORP              | GB        |    361878 | NS      | $687568.20    | 0.54%             |  |  |  | No            |                  1 | On Loan: —       |
| Moderna Inc                                    | Moderna Inc                                           | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |    162175 | NS      | $4404673.00   | 3.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Ono Pharmaceutical Co Ltd                      | Ono Pharmaceutical Co Ltd                             | CUSIP: 000000000<br>LEI: 529900G26L4NG4GFJZ86 | Long             | EC               | CORP              | JP        |     34300 | NS      | $418577.01    | 0.33%             |  |  |  | No            |                  2 | On Loan: No      |
| Novavax Inc                                    | Novavax Inc                                           | CUSIP: 670002401<br>LEI: 529900J4GJHPEPQ23205 | Long             | EC               | CORP              | US        |    371307 | NS      | $3118978.80   | 2.43%             |  |  |  | No            |                  1 | On Loan: —       |
| OMNIAB INC                                     | OMNIAB INC                                            | CUSIP: 68218J202<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     19498 | NS      | $0.19         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| OMNIAB INC                                     | OMNIAB INC                                            | CUSIP: 68218J301<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     19498 | NS      | $0.19         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| ORIC Pharmaceuticals Inc                       | ORIC Pharmaceuticals Inc                              | CUSIP: 68622P109<br>LEI: 54930033FJRNEYBW0L25 | Long             | EC               | CORP              | US        |    100406 | NS      | $1321342.96   | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Takeda Pharmaceutical Co Ltd                   | Takeda Pharmaceutical Co Ltd                          | CUSIP: 000000000<br>LEI: 549300ZLMVP4X0OGR454 | Long             | EC               | CORP              | JP        |    149900 | NS      | $4045425.27   | 3.16%             |  |  |  | No            |                  2 | On Loan: No      |
| Pacific Biosciences of California Inc          | Pacific Biosciences of California Inc                 | CUSIP: 69404D108<br>LEI: 529900F1BWRE1M0KZN89 | Long             | EC               | CORP              | US        |    664509 | NS      | $1554951.06   | 1.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                               | Roche Holding AG                                      | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     13672 | NS      | $4428636.61   | 3.45%             |  |  |  | No            |                  2 | On Loan: No      |
| Regeneron Pharmaceuticals Inc                  | Regeneron Pharmaceuticals Inc                         | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      9030 | NS      | $5885754.00   | 4.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                       | Revolution Medicines Inc                              | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |    108379 | NS      | $6377020.36   | 4.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Rigel Pharmaceuticals Inc                      | Rigel Pharmaceuticals Inc                             | CUSIP: 766559702<br>LEI: 529900KPTNUS5J8K9K66 | Long             | EC               | CORP              | US        |     43709 | NS      | $1380330.22   | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Twist Bioscience Corp                          | Twist Bioscience Corp                                 | CUSIP: 90184D100<br>LEI: 549300T23BL59LCOH584 | Long             | EC               | CORP              | US        |    141062 | NS      | $4639529.18   | 3.62%             |  |  |  | No            |                  1 | On Loan: —       |
| Vir Biotechnology Inc                          | Vir Biotechnology Inc                                 | CUSIP: 92764N102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    224114 | NS      | $1335719.44   | 1.04%             |  |  |  | No            |                  1 | On Loan: —       |
| BlackRock Funds III                            | BlackRock Cash Funds: Institutional, SL Agency Shares | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |  22756972 | NS      | $22768350.33  | 17.76%            |  |  |  | No            |                  1 | On Loan: No      |
| BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES | BlackRock Cash Funds: Treasury, SL Agency Shares      | CUSIP: 066922477<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |    150000 | NS      | $150000.00    | 0.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Xencor Inc                                     | Xencor Inc                                            | CUSIP: 98401F105<br>LEI: 549300V5IF65437JKG30 | Long             | EC               | CORP              | US        |    168064 | NS      | $2472221.44   | 1.93%             |  |  |  | No            |                  1 | On Loan: —       |
| SK Bioscience Co Ltd                           | SK Bioscience Co Ltd                                  | CUSIP: 000000000<br>LEI: 988400F5SGZAXEGIAM36 | Long             | EC               | CORP              | KR        |     64999 | NS      | $2308049.65   | 1.80%             |  |  |  | No            |                  2 | On Loan: No      |
| Chicago Mercantile Exchange                    | XAV HEALTH CARE DEC25                                 | CUSIP: 000000000<br>LEI: SNZ2OJLFK8MNNCLQOF39 | N/A              | DE               |  | US        |         2 | NC      | $8832.96      | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Valneva SE                                     | Valneva SE                                            | CUSIP: 000000000<br>LEI: 969500DIVIP5VKNW4948 | Long             | EC               | CORP              | FR        |    358319 | NS      | $1671914.40   | 1.30%             |  |  |  | No            |                  2 | On Loan: —       |
| GSK PLC                                        | GSK PLC                                               | CUSIP: 000000000<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |    217600 | NS      | $5094764.18   | 3.97%             |  |  |  | No            |                  2 | On Loan: No      |
| BeOne Medicines Ltd                            | BeOne Medicines Ltd                                   | CUSIP: 000000000<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |    223900 | NS      | $5383071.14   | 4.20%             |  |  |  | No            |                  2 | On Loan: No      |
| CRISPR Therapeutics AG                         | CRISPR Therapeutics AG                                | CUSIP: 000000000<br>LEI: 506700O6IRRIQLT3W370 | Long             | EC               | CORP              | CH        |      8103 | NS      | $518510.97    | 0.40%             |  |  |  | No            |                  1 | On Loan: —       |

### Signature

**Date Signed:** 2025-11-28

**Name of Applicant:** iShares Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer